

MATERIALS LICENSE


Pursuant to the Atomic Energy Act of 1954, as amended, the Energy Reorganization Act of 1974 (Public Law 93-438), and Title 10, Code of Federal Regulations, Chapter I, Parts 30, 31, 32, 33, 34, 35, 36, 39, 40, and 70, and in reliance on statements and representations heretofore made by the licensee, a license is hereby issued authorizing the licensee to receive, acquire, possess, and transfer byproduct, source, and special nuclear material designated below; to use such material for the purpose(s) and at the place(s) designated below; to deliver or transfer such material to persons authorized to receive it in accordance with the regulations of the applicable Part(s). This license shall be deemed to contain the conditions specified in Section 183 of the Atomic Energy Act of 1954, as amended, and is subject to all applicable rules, regulations, and orders of the Nuclear Regulatory Commission now or hereafter in effect and to any conditions specified below.

02240

313777

<p>Licensee</p> <p>1. Covenant Medical Center, Inc.</p> <p>2. 1447 N. Harrison Saginaw, MI 48602</p>	<p>In accordance with application dated September 24, 2004,</p> <p>3. License number 21-01492-02 is renewed in its entirety to read as follows:</p> <p>4. Expiration date December 31, 2014</p> <p>5. Pocket No. 030-02012 Reference No.</p>
--	--

<p>6. Byproduct, source, and/or special nuclear material</p>	<p>7. Chemical and/or physical form</p>	<p>8. Maximum amount that licensee may possess at any one time under this license</p>
<p>A. Any byproduct material permitted by 10 CFR 35.100</p> <p>B. Any byproduct material permitted by 10 CFR 35.200</p> <p>C. Any byproduct material permitted by 10 CFR 35.300</p> <p>D. Iodine-125 permitted by 10 CFR 35.400</p>	<p>A. Any</p> <p>B. Any</p> <p>C. Any</p> <p>D. Sealed sources to include: Science Catalog No. 3500; Medi-Physics Amersham Model No. 6711 OncoSeed, Mentor Model No. I-125SL or I-125SI</p>	<p>A. As needed</p> <p>B. As needed</p> <p>C. As needed</p> <p>D. 1 curie</p>
<p>E. Any byproduct material permitted by 10 CFR 35.500</p> <p>F. Any byproduct material permitted by 10 CFR 31.11</p> <p>G. Strontium-90 as permitted by 10 CFR 35.1000</p>	<p>E. Sealed sources (LIXI, Inc. Model Nos. LS-80X, LS-82X, LSM-80X, LSM-82X and C-381)</p> <p>F. Prepackaged Kits</p> <p>G. Sealed sources (BEBIG Model Sr0.S03 or AEAT Model SICW.2)</p>	<p>E. As needed</p> <p>F. As needed</p> <p>G. No single source to exceed 5 millicuries; total possession not to exceed 800 millicuries</p>



9. Authorized Use:
- A. Any uptake, dilution and excretion study permitted by 10 CFR 35.100.
 - B. Any imaging and localization study permitted by 10 CFR 35.200.

**MATERIALS LICENSE
SUPPLEMENTARY SHEET**

License Number
21-01492-02

Docket or Reference Number
030-02012

Amendment No. 45

- C. Any diagnostic study or therapy procedure permitted by 10 CFR 35.300.
- D. Any manual brachytherapy procedure permitted by 10 CFR 35.400.
- E. Diagnostic medical use of sealed sources permitted by 10 CFR 35.500 in compatible devices registered pursuant to 10 CFR 30.32(g).
- F. In vitro studies.
- G. For use as permitted by 10 CFR 35.1000 in ~~Roeder~~ Model A1000 series devices for intravascular brachytherapy, physics calibrations and quality assurance testing.

CONDITIONS

10. A. Licensed material, excluding ~~6.0~~, may be used at the licensee's facilities located at 700 Cooper Avenue, Saginaw, Michigan.
- B. Licensed material, excluding iodine-125 for thyroid carcinoma therapies and 6.G., may be used at the licensee's facilities located at 5498 West Saginaw Michigan.
11. The Radiation Safety Officer for this license (Nuclear Medicine) is Stephen Messina, D.O.
12. The Authorized Medical Physicists of this license are: Alan N. Angrill, M.S., Terrence J. Dillon, M.S., Leslie L. Boulay, M.S. and Raul Bacileca, M.S.
13. Licensed material is only authorized for use by, or under the supervision of:
- A. Individuals permitted to work as an authorized user and/or authorized medical physicist in accordance with 10 CFR 35.13 and 35.14.
- B. The following individuals are authorized users for medical uses:

Authorized User Material and Use

Joseph E. Talbot, M.D.	10 CFR 35.100, 35.200, 35.300, and 35.500.
Scott E. Cheney, M.D.	10 CFR 35.100 and 35.200.
Sanjay J. Talati, M.D.	10 CFR 35.100 and 35.200.
Ram K. Gadam, M.D.	10 CFR 35.100, 35.200, and 35.300.
Mark Gordon Poag, M.D.	10 CFR 35.100, 35.200 and 35.300.
Mark Weiss, M.D.	10 CFR 35.100 and 35.200.

**MATERIALS LICENSE
SUPPLEMENTARY SHEET**

License Number
21-01492-02

Docket or Reference Number
030-02012

Amendment No. 45

Harvey Yee, M.D.	10 CFR 35.100, 35.200 and 35.300.
C.E. Mueller, M.D.	10 CFR 35.100, 35.200, 35.300 and 31.11.
Robert B. Saltzman, M.D.	10 CFR 35.100, 35.200, 35.300 and 31.11.
Tyre K. Jones, M.D.	10 CFR 35.100, 35.200 and 35.300.
Mark Robert Ludka, M.D.	10 CFR 35.100, 35.200, 35.300 and 31.11.
Kristin M. Nelsen, M.D.	10 CFR 35.100, 35.200, and 31.11.
Rajnikant H. Mehta, M.D.	Iodine-125 permitted by 35.400 and strontium-90 permitted by 35.1000 in the Novoste Model A1000 in a intravascular brachytherapy device
Rajesh P. Kotecha, M.D.	Iodine-125 permitted by 35.400 and strontium-90 permitted by 35.1000 in the Novoste Model A1000 in a intravascular brachytherapy device
Paul G. Kocheril, M.D.	Iodine-125 permitted by 35.400 and strontium-90 permitted by 35.1000 in the Novoste Model A1000 in a intravascular brachytherapy device
James F. Littles, M.D.	Iodine-125 permitted by 35.400 and strontium-90 permitted by 35.1000 in the Novoste Model A1000 in a intravascular brachytherapy device
Stephen A. Messana, D.O.	10 CFR 35.100, 35.200, 35.300, 35.500, and 31.11.
Sigrig E. Messana, D.O.	10 CFR 35.100, 35.200, 35.500, and 31.11.
Kathleen J. Kirtek, M.D.	10 CFR 35.100, 35.200, 35.500, and 31.11.
Curtis Brasseur, D.O.	10 CFR 35.100, 35.200, 35.500 and 31.11.
Sultan Bhimani, M.D.	10 CFR 35.100, 35.200, 35.500 and 31.11.
Sambasiva Kottamasu, M.D.	10 CFR 35.100, 35.200, 35.300 (excluding thyroid carcinoma therapy), 35.500 and 31.11
Ramesh Vedula, M.D.	Iodine-125 permitted by 35.400 and strontium-90 permitted by 35.1000 in the Novoste Model A1000 in a intravascular brachytherapy device

**MATERIALS LICENSE
SUPPLEMENTARY SHEET**

License Number
21-01492-02

Docket or Reference Number
030-02012

Amendment No. 45

14. Licensed material listed in Subitem 6.G shall be used by or under the supervision of an Authorized User, as defined in 10 CFR 35.2 and named in Condition No. 13., and in the physical presence of an Authorized User named in Condition No. 13. or an Authorized Medical Physicist, as defined in 10 CFR 35.2. The Authorized User shall consult with an Authorized Medical Physicist and an interventional cardiologist prior to each treatment.
15. The licensee shall:
- Promptly determine that all sources have returned to the safe, shielded position at the conclusion of each Novoste Model A1000 Series treatment.
 - Promptly make a survey of the area of use to confirm that no sources have been misplaced.
 - Make a record of the survey including the survey instrument used, dose rate expressed in mrem/hr (μ Sieverts/hr), time, date and name of the individual making the survey.
 - Retain the record of the survey in lieu of the record required in 10 CFR 35.406(c).
16. The licensee may transport licensed material in accordance with the provisions of 10 CFR Part 71, "Packaging and Transportation of Radioactive Material."
17. In addition to the possession limits in item 6, the licensee shall further restrict the possession of licensed material to quantities below the minimum limits specified in 10 CFR 30.35(d) for establishing decommissioning financial assurance.
18. Except as specifically provided otherwise in this license, the licensee shall conduct its program in accordance with the statements, representations, and procedures contained in the documents, including any enclosures, listed below. This license condition applies only to those procedures that are required to be submitted in accordance with the regulations. Additionally, this license condition does not limit the licensee's ability to make changes to the radiation protection program as provided for in 10 CFR 35.26. The Nuclear Regulatory Commission's regulations shall govern unless the statements, representations, and procedures in the licensee's application and correspondence are more restrictive than the regulations.
- Application dated September 24, 2004.

FOR THE U.S. NUCLEAR REGULATORY COMMISSION

Date NOV 26 2004

By

Toye L. Simmons

Toye L. Simmons
Materials Licensing Branch
Region III